| 摘要: |
| 目的 观察99锝-亚甲基二膦酸盐注射液(99Tc-MDP,商品名：云克)联合甲泼尼龙琥珀酸钠粉针治疗甲状腺相关眼病(TAO)的疗效。方法 将病程都在1年以内的42例TAO患者随机分为2组:实验组应用99Tc-MDP联合甲泼尼龙琥珀酸钠粉针冲击治疗,口服泼尼松片40 mg/d,1个月后停药；对照组应用甲泼尼龙琥珀酸钠粉针冲击治疗,口服泼尼松片40 mg/d,4个月后停药。评价治疗前后两组患者的突眼度及TAO眼病活动性,并进行组间比较。结果 两组TAO的临床症状均有改善,其中在突眼度方面,实验组有效率为90.9%(20/22),对照组有效率为65%(13/20),两组差异有统计学意义(P<0.05)。而两组TAO眼病活动性治疗效果比较,差异无统计学意义(P>0.05)。实验组未出现与99Tc-MDP有关的不良反应。结论 99Tc-MDP联合甲泼尼龙治疗甲状腺相关眼病在突眼度的改善方面具有较好的疗效,无明显不良反应,同时缩短了糖皮质激素的使用疗程。 |
| 关键词: 99锝-亚甲基二膦酸盐 甲泼尼龙；Graves眼病 |
| DOI：10.3724/SP.J.1008.2012.00808 |
| 投稿时间：2012-02-15修订日期：2012-05-07 |
| 基金项目: |
|
| 99Tc-MDP combined with methylprednisolone sodium succinate in treatment of thyroid-associated ophthalmopathy: an analysis of clinical efficacy |
| WANG Ling,CHEN Li-ping,XING Jian-qiang |
| (Department of Ophthalmology, Affiliated Hospital of Hainan Medical College, Haikou 570102, Hainan, China) |
| Abstract: |
| ObjectiveTo observe the efficacy of technetium-99 methylenediphosphonate (99Tc-MDP) combined with methylprednisolone sodium succinate (MSS) on thyroid-associated ophthalmopathy (TAO). MethodsTotally 42 TAO patients with a disease course less than 1 years were randomly divided into two groups: the experimental group was treated with 99Tc-MDP combined with MSS (40 mg/d for one month) and the control group was treated with MSS alone (40 mg/d for four months). The degree of exophthalmos and TAO activity were observed before and after treatment and were compared between the two groups. ResultsThe clinical symptoms of TAO were improved in both groups. The effective rate for exophthalmos degree was 90.9%(20/22) in the experimental group and 65%(13/20) in the control group, and there was significant difference between the two groups ( P<0.05 ). The clinical efficacies for TAO ophthalmopathy activity were not significantly different between the two groups (P>0.05 ). No 99Tc-MDP-associated adverse reactions were found in the experimental group. Conclusion99Tc-MDP combined with MSS shows satisfactory effect for treatment of thyroid-associated ophthalmopathy, especially for exophthalmia, with no 99Tc-MDP-associated adverse reactions, and can shorten the period of corticosteroid treatment. |
| Key words: technetium-99 methylenediphosphonate methylprednisolone Graves ophthalmopathy |
